摘要
目的探讨肠道益生菌复合制剂预防重症监护病房抗生素相关性腹泻临床效果。方法将181例ICU患者随机分为预防组(90例),对照组(91例),预防组在对照组广谱抗感染及对症治疗的基础上加用乳酸杆菌复合制剂。观察两组患者发生抗生素相关性腹泻情况。结果抗生素相关性腹泻在预防组出现8/90例(8.89%),对照组出现23/91例(25.27%),两组相比差异有显著性(P<0.05),发生率绝对值下降16.38%。结论乳酸杆菌复合制剂可以预防和减少ICU抗生素相关性腹泻发病率,降低住院费用。
Objective To assess the preventive efficacy of a probiofie agent containing laetobaeillus on antibioticassociated diarrhoea in ICU. Methods 181 patients in intensive care unit （ICU） were divided into the prevention group and the control group in random. The prevention group was given a probiotie agent containing Labctobacillus casei, L. balharicus and Strepwcoecus thermophilus ,on the basis of conventional therapy. Incidence of antibiotic-associated diarrhoea was observed in the two groups. Results 8/90 （ 8.89% ） of the prevention group developed antibiotic-associated diarrhoea compared with 23/91 （25.27%） in the control group （P 〈0. 05）. The absolute risk reduction was 16.38% （8.89% to 25.27% ）. Conclusions Consumption of a probiotie agent containing Labctobacillus casei,L bulharicus and Streptococcus thermophilus can reduce the incidence of antibiotic associated diarrhoea. This has the potential to decrease morbidity, healthcare costs and mortality if used routinely in patients in ICU.
出处
《中国微生态学杂志》
CAS
CSCD
2008年第6期596-597,599,共3页
Chinese Journal of Microecology
